Brokers Set Expectations for Edesa Biotech Q1 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Investment analysts at Zacks Small Cap issued their Q1 2026 EPS estimates for shares of Edesa Biotech in a report released on Monday, December 15th. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. Zacks Small Cap also issued estimates for Edesa Biotech’s Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.69) EPS.

EDSA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Edesa Biotech in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Edesa Biotech in a report on Monday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Edesa Biotech Stock Performance

Shares of NASDAQ EDSA opened at $1.49 on Wednesday. Edesa Biotech has a fifty-two week low of $1.44 and a fifty-two week high of $4.49. The stock has a market cap of $12.37 million, a price-to-earnings ratio of -1.10 and a beta of 0.08. The firm’s 50-day simple moving average is $1.98 and its 200 day simple moving average is $2.16.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings data on Friday, December 12th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.80. The business had revenue of $0.25 million during the quarter.

Institutional Trading of Edesa Biotech

A number of hedge funds have recently bought and sold shares of the business. Velan Capital Investment Management LP bought a new position in Edesa Biotech in the 1st quarter valued at $1,678,000. Stonepine Capital Management LLC bought a new position in Edesa Biotech during the first quarter valued at about $1,678,000. Nantahala Capital Management LLC purchased a new stake in Edesa Biotech during the first quarter worth about $1,525,000. Finally, Susquehanna International Group LLP bought a new stake in Edesa Biotech in the third quarter worth about $36,000. 5.50% of the stock is currently owned by institutional investors.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.